<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02664909</url>
  </required_header>
  <id_info>
    <org_study_id>16-058SF-2</org_study_id>
    <secondary_id>0546934781</secondary_id>
    <nct_id>NCT02664909</nct_id>
  </id_info>
  <brief_title>Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty</brief_title>
  <official_title>Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopaedic Research and Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blinded placebo-controlled clinical trial evaluating the efficacy of 1
      gram of topically applied tranexamic acid vs. saline placebo for the reduction of transfusion
      following hip hemiarthroplasty surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inpatient transfusion rate</measure>
    <time_frame>From the time of surgery until 2-4 days post-operative (length of inpatient hospital stay)</time_frame>
    <description>The rate of transfusion will be calculated for each study group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inpatient transfusion Amount</measure>
    <time_frame>2-4 days post-operative (length of inpatient hospital stay)</time_frame>
    <description>The transfusion amount will be calculated for each study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between Pre/Post-operative hemoglobin</measure>
    <time_frame>Pre-operative hemoglobin level vs. post-operative day 1 hemoglobin level</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between Pre/Post-operative hematocrit</measure>
    <time_frame>Pre-operative hematocrit level vs. post-operative day 1 hematocrit level</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of inpatient hospital stay</measure>
    <time_frame>From date of hospital admission until the date of hospital discharge or date of death from any cause, whichever comes first, assessed up to 42 days post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative complications</measure>
    <time_frame>Admission to second post-operative visit (4-6 weeks post-operative)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient hospitalization cost</measure>
    <time_frame>Collected 4-6 weeks post-operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Femoral Neck Fractures</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing hip hemiarthroplasty surgery for a displaced femoral neck fracture

        Exclusion Criteria:

          -  History of hemophilia, history of deep vein thrombosis, history of pulmonary embolism,
             history of thrombophilia, history of chronic renal failure

          -  Patients with coronary ischemia (active or within the past calendar year), patients
             who have suffered a myocardial infarction, undergone percutaneous coronary
             intervention, undergone coronary artery bypass grafting, or undergone any
             revascularization procedure within the past calendar year

          -  Patients with active subarachnoid hemorrhage, acquired defective color vision,
             patients who sustained a pathologic fracture (fracture through a neoplastic lesion),
             or patients who are pregnant

          -  Patients with a known allergy to tranexamic acid

          -  Patients taking Warfarin, Dabigatran, Rivaroxaban, Apixaban, and Fresh Frozen Plasma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael B O'Sullivan, M.D.</last_name>
    <phone>860-679-4932</phone>
    <email>osullivan@uchc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael B O'Sullivan, M.D.</last_name>
      <phone>860-679-4932</phone>
      <email>osullivan@uchc.edu</email>
    </contact>
    <investigator>
      <last_name>Vincent J Williams, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital and Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael B O'Sullivan, M.D.</last_name>
      <phone>860-679-4932</phone>
      <email>osullivan@uchc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey J Meter, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Vincent Williams</investigator_full_name>
    <investigator_title>Assistant Professor of Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <keyword>Hip Hemiarthroplasty</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Topical</keyword>
  <keyword>Blood Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Femoral Neck Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

